LOXL1 and breast cancer: Additionally, LOXL1 knockdown disrupts ECM remodelling in ILC tumours, attenuats ER signal transduction, and affects tumour growth, invasion, and metastasis in vivo, and it is linked to increased malignancy in breast cancer 48.